Abstract:FDA-approved bone morphogenetic protein 2 (BMP2) has serious side effects due to the super high dose requirement. Heparin is one of the most well-studied sulfated polymers to stabilize BMP2 and improve its functionality. However, the clinical use of heparin is questionable because of its undesired anticoagulant activity. Recent studies suggest that poly(glutamic acid) (pGlu) has the potential to improve BMP2 bioactivity with less safety concerns; however, the knowledge on pGlu's contribution remains largely unknown. Therefore, we aimed to study the role of pGlu in BMP2-induced osteogenesis and its potential application in bone tissue engineering. Our data, for the first time, indicated that both low (L-pGlu) and high molecular weight pGlu (H-pGlu) were able to significantly improve the BMP2-induced early osteoblastic differentiation marker (ALP) in MC3T3-E1 preosteoblasts. Importantly, the matrix mineralization was more rapidly enhanced by H-pGlu compared to L-pGlu. Additionally, our data indicated that only α-H-pGlu could significantly improve BMP2's activity, whereas γ-H-pGlu failed to do so. Moreover, both gene expression and mineralization data demonstrated that α-H-pGlu enabled a single dose of BMP2 to induce a high level of osteoblastic differentiation without multiple doses of BMP2. To study the potential application of pGlu in tissue engineering, we incorporated the H-pGlu+BMP2 nanocomplexes into the collagen hydrogel with significantly elevated osteoblastic differentiation. Furthermore, H-pGlu-coated 3D porous gelatin and chitosan scaffolds significantly enhanced osteogenic differentiation through enabling sustained release of BMP2. Thus, our findings suggest that H-pGlu is a promising new alternative with great potential for bone tissue engineering applications.

Preparation, Structure and Bmp-2 Controlled Release of Heparin-Conjugated Hyaluronan Microgels

Novel PCL-based Honeycomb Scaffolds As Drug Delivery Systems for Rhbmp-2

Studies on Recombinant Human Bone Morphogenetic Protein 2 Loaded Nano-Hydroxyapatite/Silk Fibroin Scaffolds

Robust, Highly Elastic and Bioactive Heparin-Mimetic Hydrogels

Chitosan-Based Hydrogels Embedded with Hyaluronic Acid Complex Nanoparticles for Controlled Delivery of Bone Morphogenetic Protein-2

Biomimetic ECM coatings for controlled release of rhBMP-2: construction and biological evaluation

In vitro sustained release of recombinant human bone morphogenetic protein-2 microspheres embedded in thermosensitive hydrogels

Modulating the release of bioactive molecules of human mesenchymal stromal cell secretome: Heparinization of hyaluronic acid-based hydrogels

An In Situ Gel-Forming Heparin-Conjugated PLGA-PEG-PLGA Copolymer

In Situ Controlled Release Of Rhbmp-2 In Gelatin-Coated 3d Porous Poly(Epsilon-Caprolactone) Scaffolds For Homogeneous Bone Tissue Formation

Heparin-mediated delivery of bone morphogenetic protein-2 improves spatial localization of bone regeneration

Sustained release of heparin on enlarged-pore and functionalized MCM-41.

Spatially-controlled Distribution of HACC in Mineralized Collagen Coatings for Improving Rhbmp-2 Loading and Release Behavior.

Heparinized chitosan stabilizes the bioactivity of BMP-2 and potentiates the osteogenic efficacy of demineralized bone matrix

An Injectable Click-Crosslinked Hyaluronic Acid Hydrogel Modified with a BMP-2 Mimic Peptide as a Bone Tissue Engineering Scaffold

Porous Nano-Ha/collagen/plla Scaffold Containing Chitosan Microspheres for Controlled Delivery of Synthetic Peptide Derived from BMP-2.

In situ controlled release of rhBMP-2 in gelatin-coated 3D porous poly(ε-caprolactone) scaffolds for homogeneous bone tissue formation.

Heparin-conjugated injectable hydrogels with sustained releasing capability for promotion of H-type vessels formation and rat femoral bone defects repair

Thyrocalcitonin deficiency after treatment of thyroid disorders by surgery or radioiodine.

In vivo evaluation of MMP sensitive high-molecular weight HA-based hydrogels for bone tissue engineering.

High Molecular Weight Poly(glutamic acid) to Improve BMP2-Induced Osteogenic Differentiation